BioCardia's CardiAMP Therapy Shows Durable Gains in Chronic Myocardial Ischemia Trial
Event summary
- BioCardia presented CardiAMP CMI trial results at EuroPCR 2026, showing durable improvements in exercise tolerance and reduced angina frequency over two years.
- The trial involved 24 patients with refractory angina who had exhausted all conventional treatment options.
- Patients experienced an average increase in exercise tolerance of 179 seconds and an 82% reduction in angina episodes by six months.
- The CardiAMP therapy uses a patient’s own bone marrow cells delivered via a minimally invasive catheter-based procedure.
The big picture
BioCardia's positive trial results position CardiAMP as a potential breakthrough for patients with refractory angina, a condition affecting 600,000 to 1.8 million people in the U.S. The therapy addresses a critical unmet need in cardiovascular medicine, where conventional treatments often fail. The durable improvements in exercise tolerance and angina reduction could make it a key player in the cell therapy space, provided it navigates regulatory and reimbursement hurdles effectively.
What we're watching
- Regulatory Pathway
- Whether the FDA Breakthrough Therapy designation will expedite the approval process for CardiAMP Cell Therapy.
- Market Adoption
- The pace at which CardiAMP therapy could gain acceptance among physicians and patients with refractory angina.
- Reimbursement Dynamics
- How Medicare reimbursement coverage will impact the commercial viability of the therapy.
Related topics